NewVale Capital

NewVale Capital operates as a growth equity firm dedicated to investing in and scaling businesses within the life sciences services and enabling technology sectors. The firm focuses on companies providing essential infrastructure across drug discovery, clinical research, manufacturing and supply chain, and commercialization, actively partnering with management teams to bolster commercial execution and foundational infrastructure. Their approach involves providing targeted capital and strategic support to cultivate robust, scalable platforms that serve the broader life sciences ecosystem.

The firm was founded in 2022, with key leadership including Managing Partner Todd Holmes and Executive Partners Patrick Lee and Rich Fante. Their collective experience stems from direct involvement in building, operating, and investing across the full life sciences continuum, from early-stage discovery through to therapeutic commercialization. This deep-seated industry insight informed the strategic decision to establish a firm exclusively focused on the service architecture that underpins life sciences advancements.

NewVale Capital’s clients are management teams of established, revenue-generating service and technology companies within the life sciences sector. The firm aims to leverage its specialized knowledge and extensive network to drive operational improvements and sustainable commercial growth for its portfolio companies. Ultimately, their vision is to build and empower the critical service providers that advance innovation and efficiency throughout the life science industry, strengthening its overall foundation for future development.